Amy C. Peterson's Insider Trades & SAST Disclosures
Amy C. Peterson's most recent trade in Exelixis Inc was a trade of 72,776 Common Stock done at an average price of $45.5 . Disclosure was reported to the exchange on May 15, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Amy C. Peterson.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Exelixis Inc | Amy C. Peterson | EVP Prod Dev & Med Aff & CMO | Sale of securities on an exchange or to another person at price $ 45.47 per share. | 15 May 2025 | 72,776 | 465,393 (0%) | 0% | 45.5 | 3,309,125 | Common Stock |
| Exelixis Inc | Amy C. Peterson | EVP Prod Dev & Med Aff & CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.75 per share. | 15 May 2025 | 40,000 | 538,169 (0%) | 0% | 21.8 | 870,000 | Common Stock |
| Exelixis Inc | Amy C. Peterson | EVP Prod Dev & Med Aff & CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 May 2025 | 40,000 | 120,000 | - | - | Option (right to buy) | |
| Exelixis Inc | Amy C. Peterson | EVP Prod Dev & Med Aff & CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 44.65 per share. | 15 May 2025 | 8,303 | 498,169 (0%) | 0% | 44.7 | 370,729 | Common Stock |
| Exelixis Inc | Amy C. Peterson | EVP Prod Dev & Med Aff & CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2025 | 159,383 | 506,472 (0%) | 0% | 0 | Common Stock | |
| Exelixis Inc | Amy C. Peterson | EVP Prod Dev & Med Aff & CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2025 | 52,192 | 347,089 (0%) | 0% | 0 | Common Stock | |
| Exelixis Inc | Amy C. Peterson | EVP Prod Dev & Med Aff & CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.05 per share. | 15 Nov 2024 | 27,224 | 294,897 (0%) | 0% | 35.0 | 954,201 | Common Stock |
| Exelixis Inc | Amy C. Peterson | EVP Prod Dev & Med Aff & CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 82,121 | 322,121 (0%) | 0% | 0 | Common Stock | |
| CytomX Therapeutics Inc | Amy C. Peterson | EVP, Chief Development Officer | Sale of securities on an exchange or to another person at price $ 1.98 per share. | 16 Mar 2023 | 4,257 | 58,433 (0%) | 0% | 2.0 | 8,425 | Common Stock |
| CytomX Therapeutics Inc | Amy C. Peterson | EVP, Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jul 2022 | 20,000 | 70,153 (0%) | 0% | 0 | Common Stock | |
| CytomX Therapeutics Inc | Amy C. Peterson | EVP, Chief Development Officer | Sale of securities on an exchange or to another person at price $ 1.42 per share. | 19 Jul 2022 | 7,463 | 62,690 (0%) | 0% | 1.4 | 10,612 | Common Stock |
| CytomX Therapeutics Inc | Amy C. Peterson | EVP, Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2022 | 200,000 | 200,000 | - | - | Stock Option (Right to Buy) | |
| CytomX Therapeutics Inc | Amy C. Peterson | EVP, Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2022 | 40,000 | 46,421 (0%) | 0% | 0 | Common Stock | |
| CytomX Therapeutics Inc | Amy C. Peterson | EVP, Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Oct 2021 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| CytomX Therapeutics Inc | Amy C. Peterson | EVP, Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Oct 2021 | 40,000 | 40,000 | - | - | Performance Stock Units (PSUs) | |
| CytomX Therapeutics Inc | Amy C. Peterson | EVP, Chief Development Officer | Grant, award, or other acquisition of securities at price $ 6.09 per share. | 31 May 2021 | 3,320 | 6,421 (0%) | 0% | 6.1 | 20,206 | Common Stock |
| CytomX Therapeutics Inc | Amy C. Peterson | EVP, Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2021 | 250,000 | 250,000 | - | - | Stock Option (right to buy) | |
| CytomX Therapeutics Inc | Amy C. Peterson | EVP, Chief Development Officer | Grant, award, or other acquisition of securities at price $ 6.39 per share. | 30 Nov 2020 | 3,101 | 3,101 (0%) | 0% | 6.4 | 19,822 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges